Halozyme prices $1.3B 1.50% convertible notes with $200M option
Halozyme Therapeutics (NASDAQ:HALO) priced $1.3B of 1.50% convertible notes, with an option adding about $200M, raising about $1.275B to fund growth after a record Q2.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.